Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kavanagh

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Kidney International|October 12, 2024
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International ForumDavid Kavanagh, Gianluigi Ardissino, Vicky Brocklebank, et al.
Blood Advances|June 4, 2020
New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCTReem Elfeky, Giovanna Lucchini, Su-Han Lum, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2018
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 GlomerulopathyAmy J Osborne, Matteo Breno, Nicolo Ghiringhelli Borsa, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 23, 2021
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and OutcomesEdwin K S Wong, Kevin J Marchbank, Hannah Lomax-Browne, et al.
Kidney International|May 11, 2020
Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathyVicky Brocklebank, Gurinder Kumar, Alexander J Howie, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Blood|September 25, 2016
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculatureDavid Kavanagh, Sarah McGlasson, Alexa Jury, et al.
Kidney International|October 12, 2024
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International ForumDavid Kavanagh, Gianluigi Ardissino, Vicky Brocklebank, et al.
Blood Advances|June 4, 2020
New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCTReem Elfeky, Giovanna Lucchini, Su-Han Lum, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2018
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 GlomerulopathyAmy J Osborne, Matteo Breno, Nicolo Ghiringhelli Borsa, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 23, 2021
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and OutcomesEdwin K S Wong, Kevin J Marchbank, Hannah Lomax-Browne, et al.
Kidney International|May 11, 2020
Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathyVicky Brocklebank, Gurinder Kumar, Alexander J Howie, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Pageof 20